Adult Dosing
Clostridium difficile-associated diarrhea
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
[Outline]
See Supplemental Patient Information
- This drug is ineffective for treatment of systemic infections as it is minimally absorbed
- Therapy is indicated only in proven or strongly suspected C. difficile infection. If prescribed in the absence of a proven or strongly suspected infection, instead of providing benefit to the patient it may increase the risk of development of drug resistant bacteria
- Acute hypersensitivity reactions, including dyspnea, rash, pruritus, and angioedema of the mouth, throat, and face have been reported; discontinue the therapy and treat appropriately
Supplemental Patient Information
- Advise patients to use this drug only for treatment of bacterial infections
- Inform patients that skipping doses or not completing the full duration of therapy may decrease the effectiveness of the immediate treatment and will also increase the likelihood that bacteria will develop resistance and will be unable to treat by fidaxomicin or any other antibacterial drugs in the future
Pregnancy Category:B
Breastfeeding: Safety Unknown. As many drugs are excreted in human milk, manufacturer advised caution when fidaxomicin is administered to a nursing woman.
18 yrs of age